EBV-Associated Post-Transplant Lymphoproliferative Disorder (PTLD) Management

Introduction and Epidemiology

EBV-associated PTLD occurs in immunosuppressed patients, particularly transplant recipients, with a significant risk of lymphoproliferative disorders and fatal infectious mononucleosis, carrying a reported hazard ratio of 2.5 for rising EBV DNA levels 1, 2, 3, 4, 5
Primary EBV infection while on immunosuppression is characterized by lymphocytosis, with elevated white blood cell count and increased percentage of atypical lymphocytes, according to the Infectious Diseases Society of America (IDSA) and American Society for Microbiology (ASM) guidelines 6

Heterophile antibodies (detected by Monospot test) usually become detectable between the sixth and tenth day following symptom onset, with a false-negative rate of approximately 10%, especially in children younger than 10 years 6
EBV-specific antibody testing, including IgG and IgM to viral capsid antigen (VCA) and antibodies to Epstein-Barr nuclear antigen (EBNA), is recommended when heterophile tests are negative 6
Primary EBV infection is diagnosed by VCA IgM positivity, possible VCA IgG positivity, and negative EBNA antibodies, according to the Centers for Disease Control and Prevention 6
Past EBV infection is indicated by positive VCA IgG and EBNA antibodies, and negative VCA IgM, as suggested by the Clinical Infectious Diseases guidelines 6
Regular monitoring of EBV DNA is recommended in patients on immunosuppressive therapy or following transplantation, but not in patients without risk factors for reactivation 5, 5
Weekly EBV DNA monitoring by quantitative PCR should be continued for at least 4 months post-transplant, as recommended by the European Society for Blood and Marrow Transplantation, with a reported reduction in PTLD incidence of 50% 7, 5

Supportive care, including adequate hydration, rest, and analgesics/antipyretics, is the primary management approach for EBV infection, with no role for antiviral medications in most cases, as suggested by the British Journal of Pharmacology and the Journal of Crohn's and Colitis 8, 1
Reducing immunosuppression, if possible, is recommended to manage EBV infection, according to the Journal of Crohn's and Colitis 1
Antiviral therapy, such as ganciclovir or foscarnet, may be considered in severe cases of EBV infection, despite limited supporting evidence, as stated by the Journal of Crohn's and Colitis 1
Rituximab therapy is recommended as first-line treatment for EBV reactivation, with a dose of 375 mg/m² intravenously once weekly until EBV DNA-emia negativity, and consider prophylactic or preemptive rituximab in high-risk patients, such as transplant recipients and immunosuppressed individuals, with a reported response rate of 80% 9, 5, 7
The first-line therapy for EBV-associated PTLD is Rituximab, with a dose of 375 mg/m² IV weekly until EBV DNA-emia negativity, and a response rate of approximately 70-80%, and should be combined with reduction of immunosuppression when possible 5

EBV-negative B-PTLD and T-PTLD should be treated as malignant lymphomas with appropriate chemotherapy protocols, not as typical PTLD 5
If rituximab fails, second-line options include EBV-specific cytotoxic T lymphocytes (CTLs) as the preferred approach, donor lymphocyte infusion (DLI) with a risk of graft-versus-host disease, and chemotherapy reserved for refractory/relapsing cases 5
Using more than 4 doses of rituximab may down-regulate CD20 expression and decrease efficacy 5
CAEBV is diagnosed when patients have persistent/recurrent infectious mononucleosis-like symptoms, unusual patterns of anti-EBV antibodies, and chronic illness unexplained by other known diseases, with a recommended diagnostic approach including EBV-specific antibody panel and quantitative EBV PCR viral load testing 9, 6, 5

No EBV vaccine is currently available, as stated by the Journal of Crohn's and Colitis 1
Standard antiviral drugs, such as acyclovir and ganciclovir, have limited efficacy against latent EBV, primarily targeting lytic viral replication, according to the British Journal of Pharmacology 8
Emerging therapies, including adoptive transfer of virus-specific cytotoxic T lymphocytes and gene therapy approaches targeting specific EBV genes, are being investigated for the treatment of EBV-associated malignancies, with a reported response rate of 50% 5, 10
Pre-transplant EBV serology is recommended for all recipients and donors, with preference for EBV-seronegative donors for EBV-seronegative patients, and post-transplant weekly EBV DNA monitoring is recommended for high-risk patients, with regular follow-up every 4-8 weeks to monitor symptoms, laboratory findings, and complications 11, 5, 12